Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT03680924 Recruiting - PTEN Gene Mutation Clinical Trials

Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome

Start date: May 11, 2018
Phase:
Study type: Observational

The purpose of this study is to gain a better understanding of access to clinical and research resources for families of children affected with a phosphatase and tensin homology (PTEN) mutation. Ultimately, the researchers hope to be able to use this information to develop a standard of care for affected individuals and their family members. Family members/legal guardians of an individual with a PTEN mutation enrolled in the Rare Diseases Clinical Research Network (RDCRN) Contact Registry will be invited via email to participate in this study.

NCT ID: NCT03680144 Not yet recruiting - Clinical trials for Metastatic Malignant Neoplasm in the Brain

Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This trial studies how well dynamic susceptibility contrast-magnetic resonance imaging (MRI) works in determining radiation necrosis and tumor progression in participants with cancer that has spread to the brain and are being treated with radiation therapy. Diagnostic procedures, such as dynamic susceptibility contrast-MRI, may improve the ability to determine indeterminate post-treatment changes seen on imaging after radiation therapy.

NCT ID: NCT03679585 Recruiting - Malignant Neoplasm Clinical Trials

Talking Pictures Social Media Intervention in Reducing Depressive Symptoms and Improving Spiritual Well-Being and Quality of Life in Adolescent and Young Adult Cancer Patients

Start date: May 31, 2017
Phase: N/A
Study type: Interventional

This clinical trial studies how well Talking Pictures social media intervention works in reducing depressive symptoms and improving spiritual well-being and quality of life in adolescent and young adult cancer patients. Talking Pictures social media intervention may help doctors better learn how to most effectively provide psychosocial support to adolescent and young adult cancer patients.

NCT ID: NCT03678337 Not yet recruiting - Cardio-oncology Clinical Trials

Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.

PICARO
Start date: September 10, 2018
Phase:
Study type: Observational [Patient Registry]

Recently, the medical management of cancer patients has considerably improved the prognosis of these patients and today some cancers are becoming "chronic diseases". As a result, new adverse effects (AEs) are observed, particularly cardiac. These "new" cardiac AEs are the consequence of a significant increase in patients life expectancy (delayed AEs not previously seen) but also the use of new pharmacological classes of anticancer drugs such as kinase inhibitors. The incidence of these cardiac AEs varies according to the patient profile and the anticancer molecules used, but their impact on the morbidity and mortality of the patients is significant. In this context, we started at the University Hospital of Caen Normandy in September 2017 a cardio-oncology program entitled "prevention and pharmacological management of cardiac adverse effects induced by drugs used in Oncology" (PICARO program). This program involves the pharmacology department (opening of a dedicated consultation), the cardiology department (opening of a dedicated ultrasound consultation), vascular medicine departement (opening of a dedicated consultation) and the oncology federation. This program aims to be regional in the future. We therefore propose to build a cohort backed up to the PICARO program to assess the regional impact of cardiac AEs of anticancer drugs and thus to be better able to specify the number of AEs, the incidence and regional prevalence of these drugs. . The constitution of this cohort is only the first step towards the constitution in the near future (2 years) of an observatory and then a regional registry of cardiac AEs induced by anticancer drugs. The objectives associated with the establishment of such a registry would be to reduce the number of cardiac AEs, the hospitalizations caused by these AEs, a better information of health professionals and patients, an improvement in the screening of patients at risk, all coming back in the context of health, clinical, epidemiological and pharmacological surveillance.

NCT ID: NCT03677531 Recruiting - Malignant Neoplasm Clinical Trials

Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy

Start date: May 31, 2018
Phase: Phase 1
Study type: Interventional

This phase I pilot trial studies how well video distraction works to decrease the use of sedation in pediatric participants during radiation therapy. Radiation treatment requires participants to lie very still (for accuracy). Many children cannot do this without sedation. Watching movies during radiation may distract children so they don't need sedation to complete treatment.

NCT ID: NCT03674710 Recruiting - Cancer Clinical Trials

A Multi-center, Prospective, Single-blind, Controlled Trial Comparing Diagnostic Value of Different EUS-FNA Techniques

EUS-FNA
Start date: December 18, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare endoscopic ultrasound guided-fine needle aspiration (EUS-FNA) with a standard 22-gauge needle using "standard suction", "slow-pull" and "wet suction" for thoracic/abdominal solid/solid-cystic lesions. Investigators intend to compare the effectiveness and safety of the three methods in order to discover the optimized technique for obtaining diagnostic material and making accurate diagnosis.

NCT ID: NCT03671226 Not yet recruiting - Clinical trials for Locally Advanced Malignant Neoplasm

Preference of Room Setting and Waiting Time in Participants With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center

Start date: February 28, 2019
Phase: N/A
Study type: Interventional

This trial studies the preference of room setting and waiting time in participants with cancer that has spread to nearby tissue or lymph nodes or other places in the body and their caregivers who are seen in the outpatient supportive/palliative care center. Room setting preferences of participants and caregivers may help to understand their opinion regarding direct rooming system in the outpatient supportive/palliative care center.

NCT ID: NCT03668769 Recruiting - Malignant Neoplasm Clinical Trials

Quitting Schedule Mobile Smartphone Application in Helping Participants to Quit Smoking

Start date: March 27, 2017
Phase: N/A
Study type: Interventional

This trial studies how well a mobile smartphone application called Quitting Schedule works in helping participants to quit smoking. Quitting Schedule is based on WebCASSI, a computer-based initiative that offered state of-the-art smoking cessation treatment and counseling to MD Anderson Cancer Center (MDACC) patients and served as a portal for non-patients to find information regarding smoking cessation advice and treatments. Quitting Schedule may help participants to quit smoking.

NCT ID: NCT03667716 Recruiting - Breast Cancer Clinical Trials

COM701 in Subjects With Advanced Solid Tumors

Start date: September 6, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with a programmed cell death protein 1 (PD-1) inhibitor.

NCT ID: NCT03666988 Not yet recruiting - Neoplasms Clinical Trials

First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

Arginine methylation mediated by protein arginine methyl-transferases (PRMTs) is an important post-translational modification of proteins involved in a diverse range of cellular processes. Misregulation and overexpression of PRMT1 (a type I PRMT) has been associated with a number of solid and hematopoietic cancers. GSK3368715 leads to inhibition of tumor cell growth across tumor types with cytotoxic response observed in lymphoma, acute myeloid leukemia (AML) and a subset of solid tumor cell lines. This study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK33368715 in subjects with relapsed/refractory DLBCL and selected solid tumors with frequent methyl-thioadenosine phosphorylase (MTAP)-deficiency. The study will consist of two parts. In Part 1 (Dose Escalation) escalating doses of GSK3368715 will be evaluated and recommended phase 2 dose (RP2D) will be established in subjects with selected solid relapsed/refractory tumors. In Part 2 (Dose Expansion), this RP2D will be further investigated in two expansion cohorts; subjects with DLBCL (Expansion Cohort 2A) and relapsed/refractory solid tumors including pancreatic, bladder, and non-small cell lung cancer (NSCLC)(Expansion Cohort 2B). The study includes a screening period, an intervention period and follow up. Approximately 40 subjects will be enrolled in Part 1 and 141 will be enrolled in Part 2.